Literature DB >> 10716690

Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus.

J L Van Laethem1, M O Peny, I Salmon, M Cremer, J Devière.   

Abstract

BACKGROUND: Eradication of Barrett's mucosa by thermal or photoablation combined with high doses of proton pump inhibitors is a potentially attractive strategy in the management of this preneoplastic condition. However, major concerns of this method are the persistence of residual metaplastic glands beneath the new squamous epithelium and the absence of any knowledge of its impact on long term outcome. CASE REPORT: The case of an intramucosal adenocarcinoma diagnosed 18 months after apparently complete squamous re-epithelialisation achieved using argon plasma coagulation and high dose omeprazole (40 mg/daily) is reported in a 68 year old patient presenting initially with a Barrett's oesophagus without dysplasia. Intramucosal adenocarcinoma was located under the new squamous layer and presented as a bulging area covered by the squamous epithelium. It probably originates from residual metaplastic glands after therapy although a pre-existing tumour cannot be definitely excluded.
CONCLUSION: This observation might question future application of this experimental endotherapy in non-dysplastic Barrett's oesophagus. It suggests that the residual glands might still be premalignant and that the early diagnosis of neoplastic changes might be compromised by the squamous re-epithelialisation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10716690      PMCID: PMC1727885          DOI: 10.1136/gut.46.4.574

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  48 in total

1.  [Barrett esophagus: ablative methods of treatment].

Authors:  M Jung; C Ell
Journal:  Internist (Berl)       Date:  2003-01       Impact factor: 0.743

2.  Argon plasma coagulation therapy for ablation of Barrett's oesophagus.

Authors:  J Deviere
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

3.  Ablative mucosectomy is the procedure of choice to prevent Barrett's cancer.

Authors:  R C Fitzgerald
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

4.  Sixteen-year follow-up of Barrett's esophagus, endoscopically treated with argon plasma coagulation.

Authors:  Mariana Milashka; Annabelle Calomme; Jean Luc Van Laethem; Daniel Blero; Pierre Eisendrath; Olivier Le Moine; Jacques Devière
Journal:  United European Gastroenterol J       Date:  2014-10       Impact factor: 4.623

Review 5.  Current status of ablative therapies in esophageal disorders.

Authors:  P Sharma
Journal:  Curr Gastroenterol Rep       Date:  2001-06

Review 6.  Prevention of adenocarcinoma by reversing Barrett's esophagus with mucosal ablation.

Authors:  Richard E Sampliner
Journal:  World J Surg       Date:  2003-08-18       Impact factor: 3.352

Review 7.  Surveillance in Barrett's oesophagus: a personal view.

Authors:  K K Basu; J S de Caestecker
Journal:  Postgrad Med J       Date:  2002-05       Impact factor: 2.401

8.  Endoscopic therapy of Barrett's: what more do we need to know?

Authors:  J-L Van Laethem; J Devière
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

9.  Biodegradable esophageal stent placement does not prevent high-grade stricture formation after circumferential mucosal resection in a porcine model.

Authors:  Eric M Pauli; Steve J Schomisch; Joseph P Furlan; Andrea S Marks; Amitabh Chak; Richard H Lash; Jeffrey L Ponsky; Jeffrey M Marks
Journal:  Surg Endosc       Date:  2012-06-09       Impact factor: 4.584

Review 10.  Endoscopic management of Barrett's esophagus: advances in endoscopic techniques.

Authors:  Ali Azarm; Ismet Lukolic; Meenal Shukla; Ronald Concha-Parra; Frank Gress
Journal:  Dig Dis Sci       Date:  2012-07-04       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.